NEWPORT BEACH, Calif.--(BUSINESS WIRE)--CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, issued the following statement today regarding the announcement by Prosensa Holding N.V. (NASDAQ: RNA) that the United States Food and Drug Administration (FDA) has outlined a regulatory path forward, under an accelerated approval pathway, for drisapersen, a potential treatment for Duchenne Muscular Dystrophy (DMD):